Skip to main content
AstraZeneca Pharma India Ltd. logo

AstraZeneca Pharma India Ltd. — Investor Relations & Filings

Ticker · ASTRAZEN ISIN · INE203A01020 LEI · 335800N8M7W5JDTAHR68 BSE.NS Manufacturing
Open in API
Filings indexed 1,261 across all filing types
Latest filing 2024-09-12 Regulatory Filings
Country IN India
Listing BSE.NS ASTRAZEN

About AstraZeneca Pharma India Ltd.

https://www.astrazeneca.com/content/az-…

AstraZeneca Pharma India Ltd. is a science-led biopharmaceutical organization dedicated to the discovery, development, and commercialization of innovative prescription medicines. The company focuses on core therapeutic areas including Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology, and Rare Disease. Its product portfolio includes advanced treatments such as Tagrisso, Lynparza, and Imfinzi for various cancers, as well as Forxiga and Brilinta for metabolic and cardiovascular conditions. The company utilizes a robust global research pipeline to address complex medical challenges and improve patient outcomes. Through clinical research and specialized healthcare solutions, it delivers transformative therapies designed to treat chronic and life-threatening diseases. The organization is characterized by its commitment to scientific excellence and the delivery of high-value medical interventions.

Recent filings

Filing Released Lang Actions
Pursuant to Regulation 39(3) and other applicable regulations of SEBI (LODR) Regulations, 2015, we would like to inform you that the Registrar and Transfer Agents have informed the Company ....
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (NSE and BSE) regarding the loss of a share certificate. It references compliance with SEBI Listing Obligations and Disclosure Requirements Regulation 39(3), which pertains to share certificate loss and related procedures. The content is an announcement of an event (loss of share certificate) and the company's intention to issue a Letter of Confirmation after formalities are completed. The document is short (1675 characters) and does not contain financial data, management discussion, or report content. It is not a financial report, earnings release, or management report. It is also not a director dealing, capital change, or voting result announcement. This fits best under Regulatory Filings (RNS), which is the fallback category for regulatory announcements and compliance-related disclosures that do not fit other categories.
2024-09-12 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, issued by the Registrar and Transfer Agents confirming compliance with dematerialization procedures for securities. It is addressed to stock exchanges and signed by the company secretary. The document is short (3249 characters) and primarily serves as a compliance certificate rather than a financial report or announcement of financial results. It does not contain financial statements, management discussion, or other report content. It is a regulatory compliance filing related to securities dematerialization under SEBI regulations. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory compliance documents that do not fit other specific categories.
2024-09-09 English
We are enclosing herewith the certificate dated September 4, 2024 issued by Integrated Registry Management Services Private Limited, Registrar and Transfer Agents (RTA) of the Company confirming ....
Regulatory Filings Classification · 95% confidence The document is a certificate issued pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, confirming compliance related to dematerialization of securities for the period 01.07.2024 to 31.08.2024. It is addressed to stock exchanges and signed by the company secretary and the registrar and transfer agent. The document is short (3249 characters) and primarily serves as a compliance certificate rather than a financial report or announcement of financial results. It does not contain financial statements, management discussion, or detailed financial data. It is a regulatory compliance certificate related to securities dematerialization, fitting the category of Regulatory Filings (RNS) as it is a regulatory announcement and certification rather than a full report or financial disclosure.
2024-09-09 English
Pursuant to Regulation 39(3) and other applicable regulations of SEBI (LODR) Regulations, 2015, we would like to inform you that the Registrar and Share Transfer Agents of the Company have ....
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (NSE and BSE) regarding the loss of a share certificate. It references compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, specifically Regulation 39(3), which pertains to share certificate loss and related disclosures. The content is an announcement about a shareholder's lost share certificate and the company's intention to issue a Letter of Confirmation after formalities are completed. There is no financial data, no report attached or referenced as being published, and no mention of earnings, management changes, or other report types. This fits the category of a Regulatory Filing (RNS) as it is a regulatory announcement that does not fit into other specific categories.
2024-09-04 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges regarding the loss of a share certificate. It references compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, and informs about a shareholder's lost share certificate and the process to issue a Letter of Confirmation. The content is an official notification related to shareholding records and regulatory compliance, not a financial report, earnings release, or management discussion. It does not contain financial data or detailed report content. The document is a regulatory announcement about share certificate loss, fitting best under Regulatory Filings (RNS) as it does not fit other specific categories like Share Issue/Capital Change or Director's Dealing, since it concerns lost certificates and confirmation letters rather than share transactions or capital changes.
2024-09-04 English
Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, we would like to inform that Dr. Anil Arjundas Kukreja, currently the Vice-President - Medical Affairs and Regulatory at AstraZeneca ....
Regulatory Filings
2024-08-27 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.